Arjan C Lankester
Overview
Explore the profile of Arjan C Lankester including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
164
Citations
3637
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Vissers L, van der Burg M, Lankester A, Smiers F, Bartels M, Mohseny A
J Clin Med
. 2023 Nov;
12(22).
PMID: 38002797
Irreversible severe bone marrow failure (BMF) is a life-threatening condition in pediatric patients. Most important causes are inherited bone marrow failure syndromes (IBMFSs) and (pre)malignant diseases, such as myelodysplastic syndrome...
12.
Ott de Bruin L, Pico-Knijnenburg I, van Ostaijen-Ten Dam M, Weitering T, Berghuis D, Bredius R, et al.
Int J Mol Sci
. 2023 Nov;
24(21).
PMID: 37958995
In the setting of hematopoietic stem cell transplantation (HSCT), Rituximab (RTX) is used for the treatment and prevention of EBV-associated post-transplantation lymphoproliferative disease or autoimmune phenomena such as autoimmune hemolytic...
13.
Fischer M, Olbrich P, Hadjadj J, Aumann V, Bakhtiar S, Barlogis V, et al.
J Allergy Clin Immunol
. 2023 Nov;
153(1):275-286.e18.
PMID: 37935260
Background: Inborn errors of immunity (IEI) with dysregulated JAK/STAT signaling present with variable manifestations of immune dysregulation and infections. Hematopoietic stem cell transplantation (HSCT) is potentially curative, but initially reported...
14.
Ott de Bruin L, Lankester A, Staal F
Curr Opin Allergy Clin Immunol
. 2023 Oct;
23(6):467-477.
PMID: 37846903
Purpose Of Review: Provide an overview of the landmark accomplishments and state of the art of gene therapy for inborn errors of immunity (IEI). Recent Findings: Three decades after the...
15.
Cseh A, Galimard J, de la Fuente J, Isgro A, Zecca M, Garwer B, et al.
Br J Haematol
. 2023 Oct;
204(1):e1-e5.
PMID: 37795523
How important is choice of conditioning regimen in allogeneic haematopoietic stem cell transplantation (HSCT) for sickle cell disease (SCD)? We compared HSCT outcomes by conditioning regimen in paediatric patients with...
16.
von Asmuth E, Lankester A, Putter H
Am J Hematol
. 2023 Sep;
98(12):E356.
PMID: 37713530
No abstract available.
17.
von Asmuth E, Neven B, Albert M, Mohseny A, Schilham M, Binder H, et al.
Transplant Cell Ther
. 2023 Sep;
29(12):775.e1-775.e8.
PMID: 37709203
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for many inborn errors of immunity, metabolism, and hematopoiesis. No predictive models are available for these disorders. We created a...
18.
Bense J, Stiggelbout A, Lankester A, de Pagter A
Pediatr Blood Cancer
. 2023 Aug;
70(11):e30638.
PMID: 37638835
Background: Survival rates have continued to increase for pediatric hematopoietic stem cell transplantation (HSCT) for nonmalignant diseases. Despite the crucial role of caregivers in this high-intensity treatment, knowledge about long-term...
19.
Kaiser F, Janowska I, Menafra R, de Gier M, Korzhenevich J, Pico-Knijnenburg I, et al.
Blood
. 2023 Jun;
142(13):1113-1130.
PMID: 37369082
Although absence of interleukin-7 (IL-7) signaling completely abrogates T and B lymphopoiesis in mice, patients with severe combined immunodeficiency caused by mutations in the IL-7 receptor α chain (IL-7Rα) still...
20.
Achini-Gutzwiller F, Schilham M, von Asmuth E, Jansen-Hoogendijk A, Jol-van der Zijde C, Van Tol M, et al.
Blood Adv
. 2023 Jun;
7(16):4462-4474.
PMID: 37285798
Alemtuzumab (anti-CD52 antibody) is frequently prescribed to children with nonmalignant diseases undergoing allogeneic hematopoietic stem cell transplantation (HSCT) to prevent graft failure (GF) and acute graft-versus-host disease (aGVHD). The aim...